title: [Evolution of medical practice in the care of anemia amd the use of erythropoietin in chronic renal insufficiency hemodialysis in the past six years].
abstract: In order to analyze changes in anemia management in the hemodialysis patients, a retrospective survey was performed in 1999 on a representative French sample of patients in hemodialysis treated by EPO since 1992, 1994, 1996, and 1998 respectively. 368 patients were enrolled in 97 centres. At treatment initiation, some patients characteristics have significantly changed: the percentage of type 2 diabetic patients has increased marquedly from 4.5% in 1992 to 22.1% in 1998. The mean time lag between dialysis and EPO treatment initiation has decreased from 3.3 years to 0.9 on the 6-year period. Lastly, the mean hemoglobin level has increased from 73.7 to 78.5 g/l. No significant evolution in the EPO protocol was observed at the initiation as well as in the maintenance phase. An average percentage of 33.7% of patients were treated in i.v. route at initiation with a mean posology of 105.2 IU/kg (respectively 91.4 in s.c.). In the first year of follow-up, the overall mean posology was 84 IU/kg. In conclusion, this survey suggests that anemia management has been optimized over the last 6 years follow-up, including an earlier initiation of EPO treatment and a higher target of hemoglobin while EPO needs were reduced in the same time.
authors.affiliation: Institut de recherche et de formation en dialyse, Hôpital Lapeyronie, CHU, Montpellier. b-canaud@chu-montpellier.fr
authors.forename: B
authors.initials: B
authors.lastname: Canaud
authors.forename: A
authors.initials: A
authors.lastname: Richard
authors.forename: F
authors.initials: F
authors.lastname: Fagnani
authors.forename: T
authors.initials: T
authors.lastname: Moreau-Defarges
authors.forename: P
authors.initials: P
authors.lastname: Guillon
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D004921:Erythropoietin / Q000627:therapeutic use*; D005602:France / Q000453:epidemiology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D010530:Peritoneal Dialysis / Q000009:adverse effects / Q000706:statistics & numerical data; D006435:Renal Dialysis / Q000009:adverse effects* / Q000706:statistics & numerical data
chemical_list: D004921:Erythropoietin